One-time RNAi drug developer CytRx said this week that it has sold off its remaining equity interest in RXi Pharmaceuticals for roughly $7 million.
RXi was spun out of CytRx in early 2007 to carry forward its RNAi therapeutics programs (GSN 1/11/2007). In 2008, RXi went public (GSN 3/13/2008).
